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ABSTRACT
Objectives: Psoriasis is a chronic skin disease requiring a multidimensional approach, given its
varying appearance, presence of comorbidities and complex treatment regimens. Psoriasis care
is however often performed fragmented and, in case of flares, reactive with little integrated
information on and for the patient. Literature suggests a multileveled approach of psoriasis,
but the effects of its implementation have not yet been validated. The aim of this study is to
analyze the impact of a multileveled psoriasis consultation format, named PsoPlus, which has
been implemented since 2012 in the Department of Dermatology at Ghent University Hospital
in Belgium.
Methods: The patient population was divided into two groups: one following the regular
consultation and one following the PsoPlus format. Demographic data, clinical outcome and
treatment approach of psoriasis patients were compared.
Results: Patients who opted for the specialized PsoPlus consultation were younger and had
longer disease duration. Decision parameters such as disease severity and quality of life were
reported more often in the PsoPlus group. In the latter, a higher rate of patients were started on
systemic therapy compared to the regular consultation group, and reporting on adverse events
was done more frequently.
Conclusion: The implementation of a specialized consultation with comprehensive gui-
dance facilitates documentation on disease-relevant parameters such as disease severity and
quality of life. This format can be seen as a guidance for capturing data in a structured manner,
with evidence showing that it significantly impacts treatment decision, treating not only
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Introduction
Psoriasis is mainly known as a chronic skin condition
characterized by elevated plaques of erythematous
and scaly skin that may itch or burn. Psoriasis affects
2-4% of the world population [1] and has a negative
impact on Quality of Life (QoL) and work productivity
[2]. Although several compounds are available to treat
psoriasis, there is no single drug which is effective in all
cases. According to DISCOVER, a cross-sectional obser-
vational study in Belgium, nearly 40% of patients with
moderate-to-severe psoriasis were undertreated
despite the severity of their disease. This is caused by
complextreatment decisions, leading to a substantial
degree of undertreated and dissatisfied patients [3].
The rate of dissatisfaction with treatment is high
among psoriasis patients, with higher dissatisfaction
rates for exclusively topical treatments and lower dis-
satisfaction rates for treatment with biologics [4]. In
addition, psoriasis is a multi-systemic disorder requir-
ing insights that go beyond the skin as it is associated
with both physical and mental comorbidities such as
arthritis, metabolic syndrome and depression [5–10].
Therefore, an extensive and systematic patient ana-
mnesis is required to have a good overview of all
items for an optimal personalized approach.
To promote comprehensive management of psor-
iasis, some practice guidelines have been proposed. In
2013, a Spanish Working Group on Comorbidity in
Psoriasis published guidelines for monitoring comor-
bidities in psoriasis [11]. One year later, Mrowietz and
colleagues have proposed a shift towards ‘manage-
ment’-based psoriasis treatment, approaching skin
inflammation and comorbidities (cardiovascular dis-
eases and psychiatric disorders) together with negative
consequences on QoL [5]. Finally, in 2016, our group
(from Belgium) published a proposal for a multileveled
consultation format for psoriasis [12]. In this work, an
extensive consultation outline was generated, called
PsoPlus, which addresses aspects beyond comorbid-
ities and QoL in psoriasis that, in the end, affect man-
agement decisions. The consultation is executed by
two specialists: a dedicated nurse and
a dermatologist, each tackling a specific part of the
psoriasis approach.
During the PsoPlus consultation, basic assessments
such as disease severity and quality of life, are scored
by the Psoriasis Area Severity Index (PASI) and the
Dermatology Life Quality Index (DLQI) scales, respec-
tively. Besides detailed demographic information, the
patient is questioned about personal and family med-
ical history, drug history, and current complaints. For
example, one inquires into family planning, UV expo-
sure, metabolic disorders, environmental influences,
and previous and present psoriasis medication, which
are all relevant in the light of tailored psoriasis
management.
PsoPlus includes a checklist for clinical examination,
including aspects related to metabolic syndrome, e.g.
body mass index and blood pressure, and further clin-
ical investigations if required. This template can be
integrated in an electronic patient file, which facilitates
the collection of real-life data based on specific pre-
fixed indices. The extent of the checklist also reminds
the healthcare professional to inform the patient about
educational aspects of psoriasis: it draws attention to
seemingly unrelated aspects, such as UV exposure,
vaccinations and mental health, as they are queried
during the consultation. Importantly, the format urges
a close follow-up and timely referrals to other specia-
lists (e.g. rheumatology). In short, PsoPlus has the goal
to increase the quality of the whole care cycle for
psoriasis patients, hence improving treatment
outcomes.
Belgium has no echeloning system, which means
that any patient can attend a tertiary level clinic for
diagnosis and treatment, regardless of disease sever-
ity, phenotype or drug history. In our department,
two consultation formats coexist: at any time, psor-
iasis patients can choose if they visit either a PsoPlus
consultation or a general consultation (not specifically
for psoriasis, hereafter termed General consultation).
The General consultation is the regular consultation
format applied for all dermatological consultations in
our department. In the General consultation, the der-
matologist classically questions and fills out (electro-
nically) four main information domains: medical
history and current complaint, clinical examination,
diagnosis and treatment. In the PsoPlus format, two
healthcare professionals fill out a comprehensive
psoriasis specific checklist, as described previously
[12]. The PsoPlus consultation consequently takes
forty minutes, twice as long as the General
consultation.
PsoPlus consultation was implemented in the
Dermatology Department of Ghent University
Hospitalin December 2012. Although PsoPlus consul-
tation guidance intuitively seems to be useful, its real
impact and possible added value in the approach of
psoriasis has not yet been evaluated yet. The first aim
of this study was to describe the patient population
who chooses for a specialized consultation. Secondly,
an analysis was performed on the impact of the
PsoPlus format in management decisions and out-
come for the psoriasis patients.
Methodology
This paper presents the results of a 3-year implementa-
tion of PsoPlus. For the analysis, we focused on the
impact of therapeutic approach of psoriasis and com-
pared data from the PsoPlus consultation with data
from General consultation for psoriasis at our premises.
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Furthermore, patient profiles were also taken into
account when comparing both consultation formats.
We searched our database for patients with
a diagnosis of psoriasis who came for consultation in
the period of January 2013 until December 2015. We
excluded patients who came for only one consultation
in this period, patients who came more often to our
department due to non-psoriasis skin problems (e.g.
follow-up of non-melanoma skin cancer), patients who
were participating in a clinical trial, patients who did
not allow being included in the study and patients
who came interchangeably for PsoPlus and General
consultation. The included patients were subsequently
divided into two groups: PsoPlus and General consul-
tation group. This study was carried out in accordance
with the principles expressed in the Declaration of
Helsinki and written consent was obtained from all
patients to analyse their data, and data was anon-
ymized for analysis and publication.The project was
approved by the Ghent University Hospital Ethics
Committee (B6702017314642; 28th of February 2017).
Data related to demography of patients (sex, age,
disease duration, psoriasis phenotype), clinical evalua-
tion (PASI, DLQI) and treatment choices were collected.
If DLQI was missing in the General consultation, terms
related to QoL, such as ‘depression’, ‘anxiety’, ‘fatigue’,
‘embarrassment’, or ‘better QoL since the beginning of
treatment’ were sought for.Regarding treatment, we
registered psoriasis therapy used throughout the study
period, referral to other healthcare professionals, and
frequency of visits. As we analyzed a period of follow-
up (2013–2015), data from the first consultation refers
to the first consultation from January 2013, which was
not necessarily the first consultation at the depart-
ment. Missing data is reported wherever applicable
and omitted for final analysis.





Sex (male; %) 57.7 53.4 0.42
















































*Disease duration was noted in 210 of the General consultation patient files
SD: standard deviation; CPPP: chronic palmoplantarpustulosis.
Figure 1. Comparison of PsoPlus and the general consultation. Patient files were screened for data on PASI and DLQI scores,
treatment type, referrals, and number of consultations and adverse events. (a) and (b) Graphic visualization of registration rate of
PASI, DLQI in both consultation formats in unmatched and matched patients, respectively. (c) Usage of medication type at the first
and last consultation of the study period in PsoPlus (left) and General consultations (right). (d) Mean frequency of visits of matched
patients (bars represent mean ± SD). (e-f) Number of matched patients requiring referral to other specialists for comorbidities and
number of patients reporting adverse events.Colours in bar graphs: black, PsoPlus consultation; grey, General consultation.
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We performed statistical analysis comparing the
two groups using SPSS Statistics 23. We used a Chi-
Square test for analysis of the non-continuous vari-
ables, and a Mann-Whitney U test for continuous vari-
ables. Selection of matched cases was done by
propensity score matching in R (version 3.4.1) using
the nearest neighbor matching method with logistic
regression distance measure in the matchit function of
the R-Package ‘Matchit’ (version 3.0.1). The results were
considered statistically significant for p < 0.05.
Results
After searching our database, we found that from 998
psoriasis patients who came for consultation at our
department between January 2013 and
December 2015, 454 met the inclusion criteria: 156
from the PsoPlus group and 298 from the General
consultation group.
Population
The two groups did not differ significantly in sex
(p = 0.42). The PsoPlus group was significantly
younger, although this difference was small with an
average age of 45.1 years in comparison to the General
group (mean 50.1 years; Table 1).Additionally, disease
duration was also significantly longer among
PsoPluspatients (Table 1), though the difference was
very limited(2.6 years) and having very limited to no
impact on clinical decisions. Interestingly, phenotypes
differed significantly between both consultation for-
mats: PsoPlus patients were mostly patients with psor-
iasis vulgaris (almost 90%) whereas in the General
consultation group more than 30% of patients had
other subtypes of psoriasis such as chronic palmoplan-
tarpustular (CPPP), guttate, inversa, nail or capitis, as
listed in Table 1.
Clinical evaluation
PASI and DLQI were registered significantly more in
PsoPlus: 86.5% and 89.7% respectively in comparison
to General consultation (17.4% and 3.7% respectively;
Figure 1(a); p < 0.001).QoL-related terms in the General
consultation were found in only 21.1% of the files.
Therapy
To compare treatment decisions in similar population
groups, we matched population for sex, age, disease
duration and phenotype. After matching, 296 patients
were included, 148 patients from each group (Table 2).
A similar trend was observed regarding the registration
of PASI and DLQI amongst both groups (Figure 1(b);
p < 0.001).
Next, we noted the treatment types at the initiation
and end of the follow-up and found that treatment
decisions differed significantly (p < 0.001) between the
two groups, depicted in Figure 1(c). Systemic thera-
pies, including conventional and biologicals, were
more frequently prescribed in PsoPlus towards the
last registered consultation: 62.8% of patients in
PsoPluscompared to 43.9% in General consultation.
Exclusive use of topical treatment remained high in
the General consultation (from 50.7% to 43.9%)
whereas this was greatly reduced in the PsoPlus cohort
(from 43.9% to 27.7%). The prescription of biologicals
showed a steep increase in the PsoPlus group (from
16.9% to 33.1%). This was not observed in patients
from the General consultation, where only a small
increase was observed (4.1%). In contrast, conventional
drugs such as methotrexate and cyclosporine were
more frequently prescribed in the General group.
Finally, over a period of 3 months PsoPlus patients
had less frequent visits, yet this was not significant
amongst the matched cases (1.4 versus 2.9 consulta-
tions in General, p = 0.16; Figure 1(d)). In the
unmatched population this was significantly different
(p = 0.0188; data not shown). The percentage of
patients who were referred to other healthcare profes-
sionals was similar in both groups (16.9% PsoPlus and
17.6% General consultation, p = 0.87) (Figure 1(e)).
Remarkably, side effects were more prevalent in
thePsoPlus group (47.3% versus 23.6% in the General,
p < 0.001; Figure 1(f)). PsoPlus patients were thus more
likely to experience adverse events, with an odds ratio
of 2.897 (95% confidence interval: 1.758–4.804,
p < 0.0001).
Discussion
PsoPlus is a guided consultation outline with
a comprehensive checklist to be completed by both
a specialized nurse and a dermatologist. The checklist
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SD: standard deviation; CPPP: chronic palmoplantarpustulosis.
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comprises important aspects to be considered in the
evaluation of psoriasis patients, aiming to promote
a more personalized approach. In addition,we show
that the use of a structured and pre-defined electronic
patient file arranged as a checklist can be useful for
treatment decisions. Based on the low number of miss-
ing data, we show that rigorous documentation of
psoriasis-related parameters is feasible in a center of
excellence. Due to the inherent infrastructure of the
General consultation, it was not possible to compare
clinical outcome measures such as PASI scores
between both consultation formats. We were however
successful in providing evidence that the General con-
sultation lacks the rigorous registration of parameters,
such as PASI and DLQI, which are crucial for treatment
decisions. Especially for biologicals: the Belgian reim-
bursement system requires a minimal PASI score of 10,
which as a consequence of not registering PASI scores,
leads to a subjective assessment of disease severity
and treatment progress by the physician [13]. DLQI
scores can be used as additional arguments to indicate
the severity of a patient’s case from a QoL-point of
view. Hence, we interpret that the steep increase in
PsoPlus-patients on biologicals is presumably sup-
ported by the consistent registration of PASI and
DLQI scores, facilitating treatment decision to initiate
the approval process to get reimbursement for biolo-
gicals. Only 7 patients from the General consultation
were started on biologicals in the study period,
whereas only 4 out of these 7 patient files (57.1%)
includeda PASI score. Furthermore, conventional
drugs were still considered in the PsoPlus cohort dur-
ing treatment management. However, after affirming
whether previous use of conventional drugs was met
with either adverse events or insufficient clinical
response; patients were found eligible for biologicals
according to the Belgian regulation. Therefore, it is
plausible that due to the consistent registration of
potential contra-indications, PsoPlus patients were
found more often eligible for treatment with biologi-
cals, therefore favouring this type of treatment in this
group.
The increased prevalence of adverse events in
PsoPlus can be attributed to different reasons. First,
both conventional and biological drugs were more
prescribed in the PsoPlus cohort, partially explaining
the higher likelihood to adverse events. Next, PsoPlus
patients are actively asked about safety and tolerability
of their current treatments in accordance with the
specific tabs in the PsoPlus patient files. Lastly, in con-
trast to the General group, patients are first seen by
a nurse during PsoPlus. There is a possibility that the
communication with a nurse is easier and thus reveals
more information on uncomfortable experiences with
treatments than with a dermatologist.
Importantly, PsoPlus was visited less frequently,
which is an asset for chronic diseases such as psoriasis.
This is especially valuable for patients who have day-
time jobs, as consultations are often planned during
the working hours. As a consequence, patients with
chronic diseases are often forced to sacrifice holidays
for doctor visits. An additional reason for less frequent
consultations may be that withinPsoPlus the possibility
of contact via email in between consultations is pro-
vided, enabling the patient to inquire more informa-
tion related to treatment or share certain concerns
with a healthcare professional.This remains to be con-
firmed in a prospective study.
The data presented here are based on matched
populations, correcting for bias such as different phe-
notypes – which may impact treatment decision.
However, we acknowledge that this study has limita-
tions, particularly the lack of prospective data. PASI
scores were not consistently registered in the General
Consultation, making a direct comparison for disease
severity not possible with the PsoPlus cohort. This
could explain why biologicals were prescribed more
often in the PsoPlus group. Additionally, this study
lacks a cross-over design in which we inquire into the
patient’s experience and satisfaction during the
General and PsoPlus consultations; an aspect that
should be taken into account. Finally, patients could
freely choose for PsoPlus or the General consultation,
and hence were not randomized. It has been postu-
lated that PsoPlus may attract more moderate-severe
cases. However, we argue that mild cases presented to
PsoPlus as well as 45.9% of PsoPlus-patients had an
initial PASI score of less than 10. We believe this is
indicative that patients with mild psoriasis may experi-
ence a great impact on their quality of life [14,15] and
therefore opt for specialized psoriasis care
Long-term and prospective data are required to
evaluate in-depth the advantages of a structured con-
sultation format such as PsoPlus. In addition, other
parameters, such as absenteeism and indirect costs
for the patient, should be taken into consideration if
cost-effectiveness is to be evaluated. Such concept can
be found in value-based healthcare, where patients
enter a care cycle that measures the overall impact of
the given care, beyond PASI and DLQI. Additional
impact on absenteeism or comorbidities provide
more value to the patient and the overall healthcare
system both on the short and long term. In this con-
text, a comprehensive and specialized consultation
format such as PsoPlus poses an interesting tool to
investigate value-based healthcare in psoriasis.
Conclusion
In conclusion, the implementation of a structured and
specialized consultation format encompassing all
aspects of psoriasis is feasible in clinical practice and
facilitates documentation on disease-relevant para-
meters such as disease severity and quality of life.
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Moreover, this global clinical patient evaluation can
significantly impact treatment decision, in order to
adjust the psoriasis management, thereby treating
not only psoriasis but the patient as a whole.
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